Furthermore, the progression and treatment outcomes, as well as survivability at 3 years for patients with p16-positive oropharyngeal carcinoma, were significantly better, surpassing those of patients with p16-negative status. Here, CDKN2A is linked to oropharyngeal carcinoma.